26 March 2004 & 5 July 2004: The Biosafety Advisory Council issues a positive advice (with conditions) for this trial.
Trial reference:
Phase I multicentre study of TG1024 (Adenovirus interleukin 2) in patients with metastatic melanoma or other advanced solid tumor cancers